Ropinirole 0.25 mg Tablets Under Fasting Conditions
Study Details
Study Description
Brief Summary
The objective of this study was to compare the relative bioavailability of the test formulation of Ropinirole (TEVA Pharmaceuticals USA) with already marketed reference of Requip® (Manufactured by SmithKline Beecham Pharmaceuticals for GlaxoSmithKline) under fasting conditions in healthy, non-smoking, adult subjects.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Detailed Description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: 1
|
Drug: Ropinirole HCl 0.25 mg Tablets
1 x 0.25 mg
|
Active Comparator: 2
|
Drug: Requip® 0.25 mg Tablets
1 x 0.25 mg
|
Outcome Measures
Primary Outcome Measures
- Cmax (Maximum Observed Concentration of Drug Substance in Plasma) [Blood samples collected over a 24 hour period.]
Bioequivalence based on Cmax.
- AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) [Blood samples collected over a 24 hour period.]
Bioequivalence based on AUC0-t.
- AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) [Blood samples collected over a 24 hour period.]
Bioequivalence based on AUC0-inf.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Healthy (physical exam, laboratory tests, medical history and ECG), non-smoker males and/or females who were between 18 and 45 years old
Exclusion Criteria:
-
If female, pregnant, lactating or likely to become pregnant during this study.
-
History of allergy or sensitivity to ropinirole or other dopamine agonists (e.g. Corolpam®, Dostinex®, Mirapex®, Permax®, Symmetrel®) or history of any drug hypersensitivity of intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
-
History of dizziness, lightheadedness or fainting upon standing.
-
Significant history or current evidence of chronic infectious disease, system disorders, organ dysfunction, hyper/hypotension, arrythmia, tachycardia, seizure disorder or glaucoma.
-
Presence of gastrointestinal disease or history of malabsorption within the last year.
-
History of psychiatric disorders occuring within the last two years that required hospitalization or medication.
-
Presence of a medical condition requiring regular treatment with prescription drugs.
-
Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to dosing.
-
Receipt of any drug as part of a research study within 30 days prior to dosing.
-
Drug or alcohol addiction requiring treatment in the past 12 months.
-
Donation or significant loss of whole blood (480 ml or more) within 30 days or plasma within the past 14 days prior to dosing.
-
Positive test results for HIV, Hepatitis B surface antigen or Hepatitis C antibody.
-
Positive test results for drugs of abuse at screening.
-
Tobacco user within 90 days of the first study date.
-
Unable, or unwilling to tolerate multiple venipunctures.
-
Difficulty fasting or eating the standard meals that will be provided.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Novum Pharmaceutical Research Services | Houston | Texas | United States | 77042 |
Sponsors and Collaborators
- Teva Pharmaceuticals USA
Investigators
- Principal Investigator: Soran Hong, M.D., Novum Pharmaceuticals Research Services
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 10436008
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Test (Ropinirole HCl) First | Reference (Requip®) First |
---|---|---|
Arm/Group Description | 0.25 mg Ropinirole HCl Tablets test product dosed in first period followed by 0.25 mg Requip® Tablets reference product dosed in the second period. | 0.25 mg Requip® Tablets reference product dosed in first period followed by 0.25 mg Ropinirole HCl Tablets test product dosed in the second period. |
Period Title: First Intervention | ||
STARTED | 22 | 22 |
COMPLETED | 21 | 22 |
NOT COMPLETED | 1 | 0 |
Period Title: First Intervention | ||
STARTED | 21 | 22 |
COMPLETED | 20 | 22 |
NOT COMPLETED | 1 | 0 |
Period Title: First Intervention | ||
STARTED | 20 | 22 |
COMPLETED | 19 | 22 |
NOT COMPLETED | 1 | 0 |
Baseline Characteristics
Arm/Group Title | Test (Ropinirole HCl) First | Reference (Requip®) First | Total |
---|---|---|---|
Arm/Group Description | 0.25 mg Ropinirole HCl Tablets test product dosed in first period followed by 0.25 mg Requip® Tablets reference product dosed in the second period. | 0.25 mg Requip® Tablets reference product dosed in first period followed by 0.25 mg Ropinirole HCl Tablets test product dosed in the second period. | Total of all reporting groups |
Overall Participants | 22 | 22 | 44 |
Age (Count of Participants) | |||
<=18 years |
0
0%
|
0
0%
|
0
0%
|
Between 18 and 65 years |
22
100%
|
22
100%
|
44
100%
|
>=65 years |
0
0%
|
0
0%
|
0
0%
|
Sex: Female, Male (Count of Participants) | |||
Female |
5
22.7%
|
10
45.5%
|
15
34.1%
|
Male |
17
77.3%
|
12
54.5%
|
29
65.9%
|
Race/Ethnicity, Customized (participants) [Number] | |||
Black |
13
59.1%
|
17
77.3%
|
30
68.2%
|
White |
0
0%
|
1
4.5%
|
1
2.3%
|
Hispanic |
9
40.9%
|
4
18.2%
|
13
29.5%
|
Region of Enrollment (participants) [Number] | |||
United States |
22
100%
|
22
100%
|
44
100%
|
Outcome Measures
Title | Cmax (Maximum Observed Concentration of Drug Substance in Plasma) |
---|---|
Description | Bioequivalence based on Cmax. |
Time Frame | Blood samples collected over a 24 hour period. |
Outcome Measure Data
Analysis Population Description |
---|
All participants that completed the study had their samples analyzed. |
Arm/Group Title | Test (Ropinirole HCl) | Reference (Requip®) |
---|---|---|
Arm/Group Description | 0.25 mg Ropinirole HCl Tablets test product dosed in either period. | 0.25 mg Requip® Tablets reference product dosed in either period. |
Measure Participants | 40 | 40 |
Mean (Standard Deviation) [pg/mL] |
552.1
(219.01)
|
546.5
(205.72)
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Test (Ropinirole HCl), Reference (Requip®) |
---|---|---|
Comments | ||
Type of Statistical Test | Non-Inferiority or Equivalence | |
Comments | The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p<0.05). | |
Statistical Test of Hypothesis | p-Value | |
Comments | ||
Method | ||
Comments | ||
Method of Estimation | Estimation Parameter | Ratio of the T/R geometric mean x 100 |
Estimated Value | 100.16 | |
Confidence Interval |
() 90% 95.5 to 105.04 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments | Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%. |
Title | AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) |
---|---|
Description | Bioequivalence based on AUC0-t. |
Time Frame | Blood samples collected over a 24 hour period. |
Outcome Measure Data
Analysis Population Description |
---|
All participants that completed the study had their samples analyzed. |
Arm/Group Title | Test (Ropinirole HCl) | Reference (Requip®) |
---|---|---|
Arm/Group Description | 0.25 mg Ropinirole HCl Tablets test product dosed in either period. | 0.25 mg Requip® Tablets reference product dosed in either period. |
Measure Participants | 40 | 40 |
Mean (Standard Deviation) [pg*h/mL] |
4190.92
(2290.13)
|
4062.99
(2073.39)
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Test (Ropinirole HCl), Reference (Requip®) |
---|---|---|
Comments | ||
Type of Statistical Test | Non-Inferiority or Equivalence | |
Comments | The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p<0.05). | |
Statistical Test of Hypothesis | p-Value | |
Comments | ||
Method | ||
Comments | ||
Method of Estimation | Estimation Parameter | Ratio of the T/R geometric mean x 100 |
Estimated Value | 101.76 | |
Confidence Interval |
() 90% 95.45 to 108.49 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments | Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%. |
Title | AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) |
---|---|
Description | Bioequivalence based on AUC0-inf. |
Time Frame | Blood samples collected over a 24 hour period. |
Outcome Measure Data
Analysis Population Description |
---|
All participants that completed the study had their samples analyzed. |
Arm/Group Title | Test (Ropinirole HCl) | Reference (Requip®) |
---|---|---|
Arm/Group Description | 0.25 mg Ropinirole HCl Tablets test product dosed in either period. | 0.25 mg Requip® Tablets reference product dosed in either period. |
Measure Participants | 40 | 40 |
Mean (Standard Deviation) [pg*h/mL] |
4469
(2561.37)
|
4305.88
(2283.55)
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Test (Ropinirole HCl), Reference (Requip®) |
---|---|---|
Comments | ||
Type of Statistical Test | Non-Inferiority or Equivalence | |
Comments | The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p<0.05). | |
Statistical Test of Hypothesis | p-Value | |
Comments | ||
Method | ||
Comments | ||
Method of Estimation | Estimation Parameter | Ratio of the T/R geometric mean x 100 |
Estimated Value | 102.1 | |
Confidence Interval |
() 90% 95.64 to 109 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments | Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%. |
Adverse Events
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The Principal Investigator is not permitted to discuss or publish trial results.
Results Point of Contact
Name/Title | Manager, Biopharmaceutics |
---|---|
Organization | TEVA Pharmaceuticals, USA |
Phone | 1-866-384-5525 |
clinicaltrialqueries@tevausa.com |
- 10436008